HTG Molecular Diagnostics (HTGM) Skyrockets 49%
HTG Molecular Diagnostics (HTGM) , a medical diagnostics company, jumped up 49% today, leading all stocks tracked by Investors Prism. There is no news explaining the leap in share value, but it could be explained by a short squeeze. HTGM was listed as a short squeeze stock to watch, which may justify the pop.
The most recent news HTGM released was announcing that they will be presenting the next event in the RNA Profiling in Drug Discovery KOL Webcast series.
HTGM can also be considered a low-float penny stock, which often leads to volatility.
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.